Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025

About this update from Corvus Pharmaceuticals, Inc.

Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT SOUTH SAN FRANCISCO, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on November 4, 2025 at 4:30 pm ET (1:30 pm PT) to provide a business update and report third quarter 2025 financial results. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on  this link  for instant telephone access to the event. The live webcast may be accessed via the  investor relations  section of the Corvus website.  A replay of the webcast will be available on Corvus’ website for 90 days. About Corvus Pharmaceuticals Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit  www.corvuspharma.com  or follow the Company on  LinkedIn . INVESTOR CONTACT:  Leiv Lea  Chief Financial Officer  Corvus Pharmaceuticals, Inc.  +1-650-900-4522  [email protected] MEDIA CONTACT:  Sheryl Seapy  Real Chemistry  +1-949-903-4750  [email protected]

View stock analysis, news, and events for Corvus Pharmaceuticals, Inc.